問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
邱怡文
下載
2025-04-01 - 2029-09-30
Condition/Disease
The percentage change in proteinuria from baseline to week 36 was assessed based on the urine protein/creatinine ratio (UPCR) measurement of 24-hour urine samples.
Test Drug
Felzartamab
Participate Sites8Sites
Recruiting8Sites
2025-05-01 - 2026-01-30
Participate Sites4Sites
Recruiting4Sites
2025-07-01 - 2028-12-31
Participate Sites6Sites
Recruiting6Sites
2024-03-01 - 2027-12-31
Participate Sites20Sites
Not yet recruiting11Sites
2024-02-01 - 2028-12-31
Participate Sites11Sites
Recruiting11Sites
2024-10-03 - 2029-10-04
Participate Sites7Sites
Recruiting7Sites
2025-07-01 - 2030-10-31
Participate Sites5Sites
Recruiting5Sites
2025-06-13 - 2030-06-30
Participate Sites10Sites
Recruiting10Sites
2019-02-23 - 2026-12-31
2021-12-31 - 2030-12-31
全部
